Sunday, September 14, 2025 9/14/2025

tDCS to Decrease Opioid Relapse

Award Number: UH3DA047793
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2018
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

tDCS to Decrease Opioid Relapse - Buprenorphine has emerged as a leading treatment for opioid use disorder (OUD), but recipients have high early relapse rates likely due to varying degrees of dysfunction within craving and cognitive control neuronal networks. Transcranial direct current stimulation (tDCS) may have promise as adjuvant treatment for buprenorphine initiators because considerable work on addictive substances suggests treatment targeted at the dorsolateral prefrontal cortex (DLPFC; region involved in self-regulation) may reduce craving and drug consumption. We will measure behavioral and brain responses following tDCS stimulation to the DLPFC delivered during cognitive control network (CCN) priming. Participants in their first week of prescribed buprenorphine will be assessed twice using FMRI, once prior to tDCS+CCN priming and again at the completion of 5 sessions of tDCS+CCN priming (one week later). Task-based and resting state functional connectivity will be used to examine networks associated with craving (CR) and cognitive control. In the UG3 phase (n=60), FMRI will provide validation of expected changes in these networks following tDCS stimulation. Go/no go criteria for the UH3 phase will be demonstration of greater FMRI change in any node of the CR or CCN networks AND greater change in subjective craving measured prior to (outside FMRI scan) or during an FMRI cue reactivity task following the tDCS+CCN priming intervention compared to sham tDCS+CCN priming. In the UH3 phase (n=100), we will perform a larger RCT (vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained fMRI changes. Because tDCS is safe, inexpensive and portable, if this intervention provides FMRI validation of targeted brain effects and produces clinical response, it could have great impact augmenting the care of persons entering buprenorphine treatment, a population at high risk for treatment failure.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $496,284 )
2025	2025	BUTLER HOSPITAL	345 BLACKSTONE BLVD STE 2	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	001	4	4/4/2025	NON-COMPETING CONTINUATION	$49,629
2025	2025	BUTLER HOSPITAL	345 BLACKSTONE BLVD STE 2	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	4	12/17/2024	NON-COMPETING CONTINUATION	$446,655
														Subtotal = $496,284

Issue Date FY: 2024 ( Subtotal = $524,273 )
2024	2024	BUTLER HOSPITAL	345 BLACKSTONE BLVD STE 2	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	003	3	7/30/2024	EXTENSION WITH OR WITHOUT FUNDS	$0
2024	2024	BUTLER HOSPITAL	345 BLACKSTONE BLVD STE 2	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	002	3	4/16/2024	EXTENSION WITH OR WITHOUT FUNDS	$0
2024	2024	BUTLER HOSPITAL	345 BLACKSTONE BLVD	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	000	3	12/22/2023	EXTENSION WITH OR WITHOUT FUNDS	$502,784
2024	2024	BUTLER HOSPITAL	345 BLACKSTONE BLVD STE 2	PROVIDENCE	RI	02906	PROVIDENCE	USA	Drug Use and Addiction Research Programs	001	3	2/23/2024	EXTENSION WITH OR WITHOUT FUNDS	$21,489
														Subtotal = $524,273

Grand Total All Awards = $1,020,557

Top

All Categories

About

Search

Reports

Data Submission

Award Information

tDCS to Decrease Opioid Relapse

Award Number: UH3DA047793

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2018

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer